How should I convert a daily dose of 80 units of insulin degludec (Tresiba) to insulin glargine (Lantus)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Converting from Tresiba 80 Units to Lantus

Convert 80 units of Tresiba (insulin degludec) to 64 units of Lantus (insulin glargine) once daily, which represents an 80% dose reduction to minimize hypoglycemia risk during the transition.

Conversion Rationale

The FDA-approved Lantus prescribing information provides explicit guidance for converting between basal insulins 1. When transferring patients from twice-daily NPH insulin to once-daily Lantus, the recommended initial dose is 80% of the total NPH dose being discontinued to lower the likelihood of hypoglycemia 1. While this specific guidance addresses NPH conversion, the same principle applies when switching between long-acting basal insulin analogs to maintain safety.

Specific Conversion Calculation

  • Current Tresiba dose: 80 units once daily
  • Initial Lantus dose: 80 units × 0.80 = 64 units once daily
  • Timing: Administer at the same time each day 1

Critical Safety Considerations

Hypoglycemia Risk

The dose reduction to 80% is specifically designed to prevent hypoglycemia during the transition period 1. Insulin degludec has a longer half-life (approximately 25 hours) compared to insulin glargine, meaning residual degludec will remain in the system for several days after switching. Starting with a lower Lantus dose accounts for this overlap.

Monitoring Requirements

  • Intensive glucose monitoring is essential during and after the conversion 2
  • Monitor fasting plasma glucose (FPG) daily for the first week
  • Check for hypoglycemia, particularly during the first 3-5 days when both insulins may overlap
  • If hypoglycemia occurs without clear cause, reduce the Lantus dose by 10-20% 2

Titration After Conversion

After the initial conversion at 80% dosing:

  1. Set an FPG goal based on individualized glycemic targets 2
  2. Use an evidence-based titration algorithm: Increase by 2 units every 3 days to reach FPG goal without hypoglycemia 2
  3. Reassess at 3-6 months to avoid therapeutic inertia 2

Common Pitfalls to Avoid

  • Do not convert unit-for-unit initially - This increases hypoglycemia risk due to overlapping insulin action
  • Do not mix or dilute Lantus with any other insulin or solution, as this alters its pharmacokinetic profile unpredictably 1
  • Rotate injection sites within the same region (abdomen, thigh, or deltoid) to reduce lipodystrophy risk 1
  • Administer at the same time daily - Lantus requires consistent timing for optimal 24-hour coverage 1

Additional Context from Research

Research data supports that when switching from degludec to glargine, dose adjustments are typically needed 3. One observational study found that the relationship between baseline degludec and follow-up glargine doses followed predictable patterns, with most patients requiring individualized adjustments over 6 months 3. The 80% starting dose provides a conservative, safe initial conversion that can then be titrated upward based on glucose response.

Adjust prandial insulin if applicable: If the patient is also on mealtime insulin, monitor postprandial glucose closely and adjust prandial doses by 10-20% if needed during the transition 2.

References

Related Questions

What is the unit‑for‑unit conversion from Basaglar (insulin glargine) to Tresiba (insulin degludec) for a patient currently taking 22 units of Basaglar?
What is the appropriate conversion of insulin glargine (Lantus) 30 U twice daily to insulin degludec (Tresiba)?
How do I convert a patient from Tresiba (insulin degludec) to Lantus (insulin glargine) in terms of dosing?
Should insulin glargine solution 100 U/mL be administered once daily in the morning?
How do I transition a patient on 75 U of Humulin N (NPH insulin) to Tresiba (insulin degludec)?
Can a typical adult dose of guaifenesin (1200 mg per day) cause diarrhea?
In a patient with hyponatremia (serum sodium 124 mEq/L), elevated BUN (120 mg/dL), anion gap 15, chloride 86 mEq/L, eGFR 18 mL/min/1.73 m², calcium 8.0 mg/dL, positive occult blood, bilateral pleural effusions, and peripheral edema, how should the occult gastrointestinal bleed be treated?
For an adult with diarrhea-predominant irritable bowel syndrome (IBS-D), which over-the-counter medication provides the greatest benefit?
What can I take to thin nasal secretions besides using a neti pot?
What type of collagen supplement is optimal for improving bone health in adults, and what dosage and accompanying nutrients (calcium, vitamin D3, etc.) are recommended?
For an adult with diarrhea‑predominant irritable bowel syndrome, is peppermint oil or wheat bran the more appropriate over‑the‑counter option?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.